Chan YY, Ho PY, Swartzrock L, Rayburn M, Nofal R, Thongthip S, Weinberg KI, Czechowicz A (2023) Non-genotoxic restoration of the hematolymphoid system in fanconi anemia. Transplant Cell Ther 29(3):164.e1-164.e9. doi: 10.1016/j.jtct.2022.08.015 PMID: 35995393
Objective: Evaluate the efficacy of different CD117 mAb agents and immunosuppression on hematopoietic stem cell (HSC) depletion, and their ability to safely establish therapeutic donor hematopoiesis post-HSCT in Fancomi Anemia (FA) disease models.
Summary: Patients with FA are particularly sensitive to genotoxic agents in the treatment of blood and immune diseases. By targeting the disease through use of a CD117 antibody conjugate to an antagonist agent, some of the sensitivities of Fancomi anemia can be circumvented compared to traditional therapeutics. The results demonstrated the efficacy of several different non-genotoxic monoclonal antibody-based conditioning strategies in Fancomi anemia.
Usage: Biotinylated CD117 mAb mixed with Streptavidin-ZAP (Anti-CD117-SAP) and was administered on Day 0. Anti-CD117-SAP was diluted with sterile PBS and administered at 1.5 mg/kg via i.v. injection.
Related Products: Streptavidin-ZAP (Cat. #IT-27), Anti-CD117-SAP (Cat. #IT-83)